Dermal Laboratories Limited

diomed.co.uk

Dermal Laboratories Limited is a Pharmaceuticals company located in Old Station Rd, Loughton, United Kingdom. Diomed Developments is a remarkable healthcare group for many reasons. Unusually for a successful business in an industry dominated by giant multi-nationals, Diomed is an independent, privately owned company. The majority of the group’s business is conducted in the UK, where several products rank as ‘brand leaders’ in their respective categories. Also, unusually for such a relatively small company, Diomed’s infrastructure reflects full vertical integration – comprising research, development, manufacture, marketing and distribution. Diomed Developments was founded in 1963 by a London physician. Originally under the name 'Dermal Laboratories', the Company set out to develop, market and distribute pharmaceutical products to dermatologists. As the business grew rapidly during the late 1960s, the Company's focus broadened from speciality products for dermatologists to include prescription products for GPs and nurses.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

news image

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Read More

Business Insights, PHARMACY MARKET

PATHAI ANNOUNCES PATHEXPLORE, AN AI-POWERED PATHOLOGY PANEL TO UNLOCK UNTAPPED INSIGHTS FROM THE TUMOR MICROENVIRONMENT

Prnewswire | April 05, 2023

news image

PathAI, a global leader in AI-powered pathology, announced the launch of PathExplore™, the world's first structured, standardized and scalable panel of human interpretable features (HIFs) offering unprecedented resolution of the tumor microenvironment (TME) from H&E whole-slide images. Powered by artificial intelligence, PathExplore1 spatially characterizes the TME with single-cell resolution, giving oncology drug developers the ability to unlock insights to inform the next p...

Read More

Pharmacy Market

XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)

Xeris Pharmaceuticals, Inc. | September 01, 2021

news image

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatmen...

Read More

Pharma Tech

CAMBREX COMPLETES FIRST PHASE OF $30 MILLION CAPACITY EXPANSION PROJECT IN HIGH POINT, NORTH CAROLINA

Cambrex | September 05, 2022

news image

Cambrex today announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina. The newly constructed space adds analytical and chemical development laboratories totaling 30,000 square feet and provides future workspace for 85 analytical and chemical development scientists. These laboratories will support the development of APIs to be manufactured in the facility's curre...

Read More
news image

PHARMACY MARKET, PHARMA TECH

CAPSIDA BIOTHERAPEUTICS AND ABBVIE ANNOUNCE EXPANSION OF COLLABORATION

Capsida Biotherapeutics | February 27, 2023

Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration. The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will...

Read More
news image

Business Insights, PHARMACY MARKET

PATHAI ANNOUNCES PATHEXPLORE, AN AI-POWERED PATHOLOGY PANEL TO UNLOCK UNTAPPED INSIGHTS FROM THE TUMOR MICROENVIRONMENT

Prnewswire | April 05, 2023

PathAI, a global leader in AI-powered pathology, announced the launch of PathExplore™, the world's first structured, standardized and scalable panel of human interpretable features (HIFs) offering unprecedented resolution of the tumor microenvironment (TME) from H&E whole-slide images. Powered by artificial intelligence, PathExplore1 spatially characterizes the TME with single-cell resolution, giving oncology drug developers the ability to unlock insights to inform the next p...

Read More
news image

Pharmacy Market

XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)

Xeris Pharmaceuticals, Inc. | September 01, 2021

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatmen...

Read More
news image

Pharma Tech

CAMBREX COMPLETES FIRST PHASE OF $30 MILLION CAPACITY EXPANSION PROJECT IN HIGH POINT, NORTH CAROLINA

Cambrex | September 05, 2022

Cambrex today announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina. The newly constructed space adds analytical and chemical development laboratories totaling 30,000 square feet and provides future workspace for 85 analytical and chemical development scientists. These laboratories will support the development of APIs to be manufactured in the facility's curre...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us